Imunon (Imunon) Net Margin %

: 0.00% (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Imunon's Net Income for the three months ended in Dec. 2023 was $-4.89 Mil. Imunon's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Imunon's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Imunon's Net Margin % or its related term are showing as below:

IMNN's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -163.08
* Ranked among companies with meaningful Net Margin % only.

Imunon Net Margin % Historical Data

The historical data trend for Imunon's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

-3,370.40

-4,296.80

-4,153.80

-7,179.60

Imunon Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																-10,586.40	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Imunon's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imunon Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, Imunon's Net Margin % distribution charts can be found below:

* The bar in red indicates where Imunon's Net Margin % falls into.

Imunon Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Imunon's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-19.515	/	0
	=	%

Imunon's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-4.888	/	0
	=	%

Imunon (NAS:IMNN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Imunon Net Margin % Related Terms

Thank you for viewing the detailed overview of Imunon's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Imunon (Imunon) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (NAS:IMNN) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

CBO:Germany

Address

997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648

Website

https://www.imunon.com

Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

Executives

James E Dentzer	director	C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Le Goff Corinne	director, officer: President and CEO	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Michael H Tardugno	officer: Chief Executive Offier	10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046-2364
Frederick J. Fritz	director	C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Kardaras Constantine John	officer: Chief Accounting Officer	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE100, LAWRENCEVILLE NJ 08648
Christine A Pellizzari	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Stacy Lindborg	director	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Donald P Braun	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Alberto R Martinez	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Jeffrey Wayne Church	officer: Chief Financial Officer
Robert W Hooper	director	C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Andreas Voss	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Egwu, Inc. Fka Egen, Inc.	10 percent owner	601 GENOME WAY, SUITE 3400, HUNTSVILLE AL 35806
Khursheed Anwer	officer: Chief Scientific Officer	C/O CELSION CORPORATION, 997 LENOX DRVIE, SUITE 100, LAWRENCEVILLE NJ 08648
Gregory L Weaver	director	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107